ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Approval of Gemcitabine For Pancreatic Cancer

August 4, 1995

Pharmacogenomics May Lead To Individualized Treatment

June 25, 2004

Eppley Probe Could Lead to Tighter Reporting By NIH supported Investigators

June 17, 1977

Susan Blumenthal Said To Be Candidate For Surgeon General

June 12, 2009

Decline In Breast Cancer Death Explained By Screening, Adjuvant Therapy, Study Finds

November 25, 2005

Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.

October 14, 2005